Hepcidin response to iron therapy in patients with non-dialysis dependent CKD: An analysis of the FIND-CKD trial

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Gaillard, Carlo A ^a   Bock, Andreas H ^b   Carrera, Fernando ^c   Eckardt, Kai Uwe ^d   Van Wyck, David B ^e   Bansal, Sukhvinder S ^f   Cronin, Maureen ^g   Meier, Yvonne ^g   Larroque, Sylvain ^g   Roger, Simon D ^h   Macdougall, Iain C ⁱ  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b CANTONAL HOSPITAL AARAU   (Switzerland)

^c DaVita ^*  (Portugal)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e DaVita HealthCare Partners   (United States)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g Vifor (International) Inc   (Switzerland)

^h Renal Research   (Australia)

ⁱ KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRITIN; FERROUS SULFATE; HEMOGLOBIN; HEPCIDIN; TRANSFERRIN; FERRIC ION; HAMP PROTEIN, HUMAN; IRON; MALTOSE;

AGED; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HORMONE BLOOD LEVEL; HUMAN; IRON DEFICIENCY ANEMIA; IRON THERAPY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; POPULATION RESEARCH; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANEMIA, IRON-DEFICIENCY; BLOOD; CLINICAL TRIAL; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; TIME FACTOR; VERY ELDERLY;

ADMINISTRATION, INTRAVENOUS; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; FEMALE; FERRIC COMPOUNDS; FERRITINS; HEPCIDINS; HUMANS; IRON; MALE; MALTOSE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS;

EID: 84975231449     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157063     Document Type: Article

References (35)

1. Nicholas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 2001; 98: 8780-8785. PMID: 11447267
2. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-7810. PMID: 11113131
3. Coyne DW. Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int 2011; 80: 240-244. doi: 10.1038/ki.2011.141 PMID: 21677632
4. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 2014; 46: 678-684. doi: 10.1038/ng.2996 PMID: 24880340
5. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, et al. Hepcidin - a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1051-1056. doi: 10.2215/CJN.05931108 PMID: 19406957
6. van der Weerd NC, Grooteman MP, Bots ML, van den Dorpel MA, den Hoedt CH, Mazairac AH, et al; CONTRAST Investigators. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS One 2012; 7: e39783. doi: 10.1371/journal.pone.0039783 PMID: 22808058
7. Mercadel L, Metzger M, Haymann JP, Thervet E, Boffa JJ, Flamant M, et al; NephroTest Study Group. The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PLoS One 2014; 9: e99781. doi: 10.1371/journal.pone.0099781 PMID: 24978810
8. Nemeth E, Ganz T. Anemia of inflammation. Hematol Oncol Clin North Am 2014; 28: 671-681 doi: 10.1016/j.hoc.2014.04.005 PMID: 25064707
9. Young B, Zaritsky J. Hepcidin for clinicians. Clin J Am Soc Nephrol 2009; 4: 1384-1387. doi: 10.2215/CJN.02190309 PMID: 19556376
10. Bregman DB, Morris D, Koch TA, He A, Goodnough LT. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol 2013; 88: 97-101. doi: 10.1002/ajh.23354 PMID: 23335357
11. Fung E, Nemeth E. Manipulation of the hepcidin pathway for therapeutic purposes. Haematologica 2013; 98: 1667-1676. doi: 10.3324/haematol.2013.084624 PMID: 24186312
12. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-1276. PMID: 15124018
13. Ford BA, Eby CS, Scott MG, Coyne DW. Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney Int 2010; 78: 769-773. doi: 10.1038/ki.2010.254 PMID: 20668427
14. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009; 75: 976-981. doi: 10.1038/ki.2009.21 PMID: 19212416
15. Kato A, Tsuji T, Luo J, Sakao Y, Yasuda H, Hishida A. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol 2008; 28: 115-121. PMID: 17943020
16. Weiss G, Theurl I, Eder S, Koppelstaetter C, Kurz K, Sonnweber T, et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest 2009; 39: 883-890. doi: 10.1111/j.1365-2362.2009.02182.x PMID: 19563467
17. van der Putten K, Jie KE, van den Broek D, Kraaijenhagen RJ, Laarakkers C, Swinkels DW, et al. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. Eur J Heart Failure 2010; 12: 943-950.
18. Takasawa K, Takaeda C, Maeda T, Ueda N. Hepcidin-25, mean corpuscular volume, and ferritin as predictors of response to oral iron supplementation in hemodialysis patients. Nutrients 2014; 7: 103-118. doi: 10.3390/nu7010103 PMID: 25551249
19. Tessitore N, Girelli D, Campostrini N, Bedogna V, Pietro Solero G, Castagna A, et al. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant 2010; 25: 3996-4002. doi: 10.1093/ndt/gfq321 PMID: 20538788
20. Chand S, Ward DG, Ng ZY, Hodson J, Kirby H, Steele P, et al. Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease. J Nephrol 2015; 28: 81-88. doi: 10.1007/s40620-014-0083-y PMID: 24687402
21. Moretti D, Goede JS, Zeder C, Jiskra M, Chatzinakou V, Tjalsma H, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood 2015; 126: 1981-1989. doi: 10.1182/blood-2015-05-642223 PMID: 26289639
22. BrǍtescu LO, Bârsan L, GârneaţǍ L, Stanciu A, Lipan M, Stancu SH, et al. Effects of additional iron doses on hepcidin-25 level in hemodialysis patients without evident iron deficiency. Int Urol Nephrol 2014; 46: 1005-1012. doi: 10.1007/s11255-014-0696-z PMID: 24800994
23. Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, et al; FIND-CKD Study Investigators. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014; 29: 2075-2084. doi: 10.1093/ndt/gfu201 PMID: 24891437
24. Macdougall IC, Bock A, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, et al; FIND-CKD Study Investigators. The FIND-CKD study - a randomized controlled trial of intravenous iron versus oral iron in nondialysis chronic kidney disease patients: background and rationale. Nephrol Dial Transplant 2014; 29: 843-850. doi: 10.1093/ndt/gft424 PMID: 24170814
25. Bansal SS, Abbate V, Bomford A, Halket JM, Macdougall IC, Thein SL, et al. Quantitation of hepcidin in serum using ultra-high-pressure liquid chromatography and a linear ion trap mass spectrometer. Rapid Commun Mass Spectrom 2010; 24: 1251-1259. doi: 10.1002/rcm.4512 PMID: 20391595
26. Pechlaner R, Kiechl S, Mayr M, Santer P, Weger S, Haschka D, et al., Correlates of serum hepcidin levels and its association with cardiovascular disease in an elderly general population. Clin Chem Lab Med 2016; 54: 151-161. doi: 10.1515/cclm-2015-0068 PMID: 26124055
27. Eguchi A, Mochizuki T, Tsukada M, Kataoka K, Hamaguchi Y, Oguni S, et al. Serum hepcidin levels and reticulocyte hemoglobin concentrations as indicators or the iron status of peritoneal dialysis patients. Int J Nephrol 2012; 2012: 239476. doi: 10.1155/2012/239476 PMID: 23193472
28. Gupta J, Mitra N, Kanetsky PA, Devaney J, Wing MR, Reilly M, et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol 2012; 7: 1938-1946. doi: 10.2215/CJN.03500412 PMID: 23024164
29. Peters HP, Laarakkers CM, Swinkels DW, Wetzels JF. Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrol Dial Transplant 2010; 25: 848-853. doi: 10.1093/ndt/gfp546 PMID: 19854845
30. Xu Y, Ding XQ, Zou JZ, Liu ZH, Jiang SH, Chen YM. Serum hepcidin in haemodialysis patients: associations with iron status and microinflammation. J Int Med Res 2011; 39: 1961-1967. PMID: 22118000
31. Camaschella C, Silvestri L. New and old players in the hepcidin pathway. Haematologica 2008; 93: 1441-1444 doi: 10.3324/haematol.13724 PMID: 18827260
32. Macdougall IC, Malyszko J, Hider RC, Bansal SS. Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin J Am Soc Nephrol 2010; 5: 1681-1689. doi: 10.2215/CJN.05990809 PMID: 20724518
33. Malyszko J. Hepcidin assays: ironing out some details. Clin J Am Soc Nephrol 2009; 4: 1015-1016. doi: 10.2215/CJN.02690409 PMID: 19470661
34. Kroot JJ, Kemna EH, Bansal SS, Busbridge M, Campostrini N, Girelli D, et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica 2009; 94: 1748-1752. doi: 10.3324/haematol.2009.010322 PMID: 19996119
35. Kroot JJ, van Herwaarden AE, Tjalsma H, Jansen RT, Hendriks JC, Swinkels DW. Second round robin for plasma hepcidin methods: first steps toward harmonization. Am J Hematol 2012; 87: 977-983. doi: 10.1002/ajh.23289 PMID: 22886770